Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
GenScript
Durvalumab Monoclonal Antibody (15D6)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 2
Durvalumab Antibody (A02031-40) in ELISA
ELISA binding of Anti-Duralumab Antibody (15D6), mAb, Mouse (GenScript, A02031-40) with Duralumab. While the antibody does not recognize the human IgG (data not shown). Coating antigen: Duralumab, 1 µg/mL. Anti-Duralumab Antibody (15D6), mAb, Mouse (GenScript, A02031-40) dilution start from 1,000 ng/mL. EC50= 7.222 ng/mL.
产品信息
A02031-40
产品规格
种属反应
Human
宿主/亚型
Mouse
/ IgG2a, kappa
分类
Monoclonal
类型
Antibody
克隆号
15D6
抗原
Durvalumab
偶联物
形式
Lyophilized
纯化类型
Protein A
保存液
PBS, pH 7.4
内含物
0.02% sodium azide
保存条件
-20°C, Avoid Freeze/Thaw Cycles
运输条件
Ambient (domestic); Wet ice (international)
产品详细信息
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Durvalumab with trade name Imfinzi, is an FDA-approved anti-cancer drug. It is known as a checkpoint inhibitor drug, developed by Medimmune/AstraZeneca. Durvalumab is a human IgG1kappa monoclonal antibody. It blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).Anti-Durvalumab Antibody (15D6), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Durvalumab.
Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below.
靶标信息
Durvalumab with trade name Imfinzi, is an FDA-approved anti-cancer drug. It is known as a checkpoint inhibitor drug, developed by Medimmune/AstraZeneca. Durvalumab is a human IgG1 kappa monoclonal antibody. It blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
